Intricacies for Posttranslational Tumor-Targeted Cytokine Gene Therapy
Figure 6
Increasing the dose of ttIL12 pDNA abrogates its therapeutic benefits. Increasing the dose by 3-fold to 30 μg pDNA per treatment resulted in a loss of inhibition by ttIL12 pDNA treatments, while the wtDNA treatments retained the ability to inhibit primary tumor growth in 4T1 primary tumor growth. Black arrows represent treatments. # represents compared to all other groups.
